Health

Lunit AI Can Help Tuberculosis Screening in Prisons, as Published in The Lancet Regional Health - Americas

* Recent study suggests that AI-based x-ray interpretation algorithms may be an efficient means to improve TB case detection among incarcerated populations * Lunit INSIGHT CXR showed the most superior performance among the tested cohort, with greater accuracy and generalizability among subgrou...

2022-12-15 21:00 1601

BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy

* A leader in creating jobs through the advancement of RNA-based therapeutics * A contributor to a high employment rate in Korea's healthcare industry BOSTON, Dec. 15, 2022 /PRNewswire/ -- BIORCHESTRA ("BIORCHESTRA" or the "Company"), a RNA therapeutics company with offices in Daejeon, South K...

2022-12-15 21:00 1500

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]  which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2...

2022-12-14 21:52 1817

E-Home Household Services Holdings Limited's subsidiary Zhong Run Launches Cloud Pharmacy Service to Address New Situation of Epidemic Prevention and Control

FUZHOU, China, Dec. 14, 2022 /PRNewswire/ -- E-Home Household Service Holdings Limited (Nasdaq: EJH) (the "Company" or "E-Home"), a provider of integrated household services inChina, today announced that the Company's subsidiary Zhongrun (Fujian) Pharmaceutical Co., Ltd. ("Zhongrun") plan to expa...

2022-12-14 21:30 2629

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

LISBON, Portugal, Dec. 14, 2022 /PRNewswire/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s devel...

2022-12-14 21:00 1847

SK Biopharmaceuticals Unveils Vision for Digital Healthcare

SK Biopharmaceuticals aims to become a 'total healthcare solution provider' as it strengthens its digital business ecosystem under 'Project ZeroTM' SK Biopharmaceuticals plans to showcase wearable devices, including CES® 2023 Innovation Awards winners'Zero GlassesTM,' 'Zero WiredTM' at the world'...

2022-12-14 10:00 1972

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...

2022-12-14 01:40 2136

Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates

Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion's SynTracer® internalization platform and ImmunoGen's proprietary linker-payload technology NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology comp...

2022-12-13 18:00 1813

Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL

SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...

2022-12-13 17:39 1871

Epidemic: Modified approach ensures maximum benefit

BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from chinadaily.com.cn: After three years of battling COVID-19, experts said China is seeing the light at the end of the tunnel as it continues to optimize measures against the epidemic.

2022-12-13 11:42 1656

Versius adopted for gynaecological and urogynaecological procedures at Frances Perry House

* Versius has been introduced at Frances Perry House, a private women's hospital inMelbourne to offer patients access to the benefits of robotic surgery for complex cases including hysterectomies CAMBRIDGE, England, Dec. 13, 2022 /PRNewswire/ -- CMR Surgical – the glo...

2022-12-13 07:00 2345

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...

2022-12-12 21:50 2241

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...

2022-12-12 21:00 1903

Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix®, a drug used for bladder c...

2022-12-12 20:59 1652

Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the first patient enrolled in phas...

2022-12-12 17:47 1616

JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) mechanism shows promising antitumor efficacy and favorable safety profile

HONG KONG, Dec. 11, 2022 /PRNewswire/ -- Akeso Inc. (9926. HK) ("Akeso") today announced that the Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal, published the mechanism of action of its Ligufalimab (AK117).The article's name is "Ligufalimab, a novel anti-CD47 antibody with no...

2022-12-12 12:59 1767

HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, Dec. 11, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. ("Nitrase"), a biopharmaceutical company deploying its NITROME platform to buil...

2022-12-12 10:10 1966

Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL)...

2022-12-11 07:15 3688

The 1st Boao International Conference on Real World Studies of Medical Products Held in Hainan

HAIKOU, China, Dec. 9, 2022 /PRNewswire/ -- On December 8, the first Boao International Conference on Real World Studies of Medical Products was held in Hainan Province, with the theme of "Real World Data Studies and Innovative Development and Supervision of Medical Products".

2022-12-09 19:54 2356

Shenzhen Holds 2022 Global Investment Promotion Conference to Build a Magnet for International Investors

SHENZHEN, China, Dec. 8, 2022 /PRNewswire/ -- Shenzhen welcomes outstanding investors from all over the world. The 2022 Shenzhen Global Investment Promotion Conference will be held inShenzhen, China on December 9. A number of major projects in the fields of information technology, artificial int...

2022-12-09 11:16 1719
1 ... 122123124125126127128 ... 280